Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients

The phenolic metabolites of the anti-HIV drug efavirenz: Evidence for distinct reactivities upon oxidation with Frémy's salt

(2014) Shrika G. Harjivan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Drug-Induced Liver Injury

(2014) Michael D. Leise et al.   MAYO CLINIC PROCEEDINGS

Dose reduction of efavirenz: an observational study describing cost–effectiveness, pharmacokinetics and pharmacogenetics

(2014) Almudena Sánchez Martín et al.   PHARMACOGENOMICS

Plasma Concentrations, Efficacy and Safety of Efavirenz in HIV-Infected Adults Treated for Tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA Trial)

(2014) Laurence Borand et al.   PLoS One

Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)

(2013) B. Hernandez-Novoa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Sensitive and Selective Liquid Chromatography/Tandem Mass Spectrometry Method for Quantitative Analysis of Efavirenz in Human Plasma

(2013) Praveen Srivastava et al.   PLoS One

HIV Coinfection With Hepatitis C Virus: Evolving Epidemiology and Treatment Paradigms

(2012) L. E. Taylor et al.   CLINICAL INFECTIOUS DISEASES

Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients

(2012) Antonio Di Biagio et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1

(2012) Jade Ghosn et al.   JOURNAL OF MEDICAL VIROLOGY

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients

(2012) A Habtewold et al.   PHARMACOGENOMICS JOURNAL

Darunavir: A Critical Review of Its Properties, Use and Drug Interactions

(2012) Josilene Chaves Ruela Corrêa et al.   PHARMACOLOGY

Pharmacology of HIV integrase inhibitors

(2012) Jessica L. Adams et al.   Current Opinion in HIV and AIDS

Safety and Pharmacokinetics of Lopinavir in HIV/HCV Coinfected Patients with Advanced Liver Disease

(2011) José L. Casado et al.   HIV CLINICAL TRIALS

Therapeutic Monitoring and Variability of Atazanavir in HIV-Infected Patients, With and Without HCV Coinfection, Receiving Boosted or Unboosted Regimens

(2011) Mario Regazzi et al.   THERAPEUTIC DRUG MONITORING

Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1

(2010) D. Croteau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients

(2010) Leonardo Calza et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study

(2010) S. Dominguez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds

(2010) Laura Else et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Viral hepatitis and HIV co-infection

(2009) Vincent Soriano et al.   ANTIVIRAL RESEARCH

Efavirenz in the therapy of HIV infection

(2009) Natella Y Rakhmanina et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients

(2009) Marta Boffito et al.   HIV CLINICAL TRIALS

Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C

(2009) J.-L. Meynard et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

(2008) Sofia A. Pereira et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry

(2008) R. ter Heine et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy

(2008) V. de Lédinghen et al.   JOURNAL OF VIRAL HEPATITIS

Single-Measurement Therapeutic Drug Monitoring of the HIV/AIDS Drugs Abacavir, Zidovudine, Lamivudine, Efavirenz, Nevirapine, Lopinavir and Nelfinavir

(2008) Josef Donnerer et al.   PHARMACOLOGY